Close Menu

More articles about Drug Discovery & Development

The companies have agreed to combine their respective offerings into a single services package for drug target identification and validation.

ZPredicta's platform is designed to integrate organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing.

The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.

The agency compiled the evolving list by drawing on information from drug labeling and the published literature and is asking stakeholders to provide feedback.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

Cellectricon is researching the spread of neurodegenerative disease-associated peptides that characterize Alzheimer's disease and Parkinson's disease.

ImiDomics has developed a platform that analyzes clinical and molecular data derived from an immune-mediated inflammatory disease biobank.

Quantitative Medicine has developed a computational drug discovery platform, called Core, that can predict the main effects of drugs on disease-associated targets.

The deal comes on the heels of a colorectal cancer-focused drug-discovery alliance that the German companies formed in early 2019.

The Scottish bioinformatics firm will crunch multi-omic datasets to assist Charles River Laboratories in "data-driven" drug discovery.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.

As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.

AbbVie researchers validated and extended a previous study to find different types of genetic evidence have varying influences on approval prospects.

In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.

Included in the deal is Diagnomics' minority stake in the Eone-Diagnomics Genome Center, a Korean provider of clinical and consumer genetics products and services.

The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

The company's revenues were generated entirely by its discovery services operations, which includes contract research for cancer drug development.

PTC Therapeutics is developing a gene therapy for the rare genetic disease AADC deficiency, which impacts the production of two key neurotransmitters.

The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.

Pages

The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.

The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.

Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.

In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.